A group led by the Department of Neurosurgery at the Brain Research Institute, Niigata University, has successfully treated a patient with a brainstem glioma harboring a rare IDH2 mutation.

A group led by the Department of Neurosurgery at the Brain Research Institute, Niigata University, has successfully treated a patient with a brainstem glioma harboring a rare IDH2 mutation. The case ...

After decades of limited progress—owing to the difficulty of treating the disease and resultant market risk—glioblastoma ...

A group at Niigata University succeeded in the treatment of a brainstem glioma patient with a rare IDH2 mutation. Brainstem gliomas with H3K27M mutation are usually refractory to temozolomide ...

Novocure's Tumor Treating Fields tech offers promise in oncology. NVCR trades at a compelling valuation after the recent ...

Promising Ewing Sarcoma Pipeline Therapies such as Vigil, Temozolomide, Irinotecan, CP-751,871, Eribulin mesylate, ...

Recommendations focus on radiation therapy and/or adjunctive therapies for WHO grade 4 adult-type diffuse glioma.

It is notable that a majority of patients in this analysis (n = 44, 88.0%) received previous temozolomide; this is despite the predominance of unmethylated MGMT promoter in H3 K27M–mutant glioma, lack ...

Actuate Therapeutics' elraglusib shows promise in metastatic pancreatic cancer. Upcoming FDA meeting may accelerate approval.

AN Essex family is racing against time to raise vital funds for their son battling the deadliest form of cancer. They are trying to raise £250,000 for life-saving treatment in Germany for their ...

US inspectors have uncovered breakdowns in drugmaking at an Indian factory owned by Sun Pharma that produces generic medications for American consumers.